Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Gsk Div is only 6.32% and look at the price of those, so wouldnt be buying just for the dividend as better and cheaper players out there above those figures
Evanescent
I agree that a reduction in HLN debt would be a good move for longer term rewards, and as such I would like to see it reduced over the next few years, even at the expense of higher dividends.
Dividend announced doesn't ammount to a full year dividend. It is a dividend for about 8.5 months.
The full year dividend for year ending April 2024 is likely to be somewhere above 1%. Its hardly fantastic, but given the 2022 we have had, and being early days for HLN, I think the future will see some increase in the dividend, and an increase in capital via a SP increase.
If an investor is holding short term, It's probably the wrong stock to have, but give it 5+ years and it's likely to be a reliable part of a diversified portfolio. I don't think it will ever be a big dividend payer, but IMHO it's likely to be a reliable payer somewhere above 4%.
If an investor wants big dividends, commodity producers are a good place to look, but they are cyclical and big dividends tend not to be consistent long term. Personally I hold a mix of both and across my portfolio it tends to even out nicely.
I will probably add more HLN as funds permit as pharma stocks are a little lite in my current holdings.
I was a little surprised to see such a small dividend on the back of such healthy looking results.
But if they are reducing the sizeable debt then it will be worth a little short term pain.....
Think it currently makes sense for minimal div while debts are high.Good to see debt drop by approx 10%
Der, 1.3% I mean
4p is 0.7% not 7%
Am i being really thick, but the dividend calculation is coming out at 7%
Maybe JP Morgan got it right ?
But dividend all the same!
No one likes the results then?
not impressed by the dividend,,, yield below 1%....
What do we think of the results
LONDON, March 2 (Reuters) - Haleon, the world's biggest standalone consumer health business, on Thursday forecast 4-6% organic revenue growth in 2023.
The London-listed company comprising health assets previously owned by GSK and Pfizer reported organic revenue growth of 9% last year.
I recently sold HLN shares. Is my capital gains calculated by subtracting the share price at the end of the first day of trading (308.35) ?
Best ignored with meaningless low and high targets often just talking their book file alongside the motley fools gla regards jack
JP Morgan Cazenove just reiterated 250.00. In September they reiterated 250.00 as new target.
As we see they are 328.00 today and over 300.00 since October. There September forecast cost investors plenty of money. There is never any comeback on these guys dud forecasts and they make plenty !!
Good spot. Hopefully the results will be in line with expectations and a dividend will be announced, and that might help the share price along. " Analysts expect a 15 per cent increase in turnover to £10.9 billion for 2022, with profits up 5 per cent to £2.3 billion and a dividend of 3p, doubling to 6p this year."
What this about Sanofi deal rumours (Daily Mail) today
Degiro has upgraded this from C to A .
Seems to meet resistance at 327p on 30/12/22 and then 17/1/23 .
Low of 311p between above dates .
This is 33rd on my Unrealised Profit page today .
"Remember 'The stock market is a device for transferring money from the impatient to the patient' Warren Buffet"
It's tough knowing when to stop being patient, though.
However, I did make the right call moving half my GSK holding into HLN. Have roughly 50/50 split now.
I guess we would be informed if a holding increases above threshold by an RNS (legal requirement)
It could be GSK off-loading its shares.....clearly they are being snapped up as the price is holding up (despite the rantings of some of the prophets of doom on this chat board)
I would much rather see this company grow on its own rather than be swallowed up by the likes of ULVR (hold shares in both)
Plan to increase my holding when the dips appear and trim when they rise...GLA
Strange how on two successive Wednesdays, sales volume has been very high, much higher than normal (63 & 79 million shares traded respectively against a daily average of around 13 million) and the SP has risen sharply after each Wednesday. Looks like major stake building to me. Would Unilever get HLN for a lot less than the 50 billion (42 billion being cash) offered a year ago? At that time the offer was ridiculed by many financial 'experts' in view of the negative effect it would have had on Unilever. Any sensible thoughts?
Remember 'The stock market is a device for transferring money from the impatient to the patient' Warren Buffet
b22
''Sell this and buy it back on the discounted placing they will undoubtedly do over the coming weeks.''
discounted - why would that be?
GSK did not want to offload the business when the equivalent of about £4 per share was offered.